However, future investigations should explore the therapeutic potential of HDAC-targeting PROTACs beyond cytotoxicity, considering their ability to enhance antitumor immune responses and overcome drug resistance in cancer immunotherapies, as evidenced by recent studies [192,193]. The gene discussed is HDAC9; the disease is cancer.